EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma

Yawen Yao, Yue Hu, Xinwang Meng, Fenyan Feng, Feng Xu, Guangji Wang, Hua Yu, Juan Li

Pharmaceutical Science Advances · 2024-12 · 2 · 100046

DOI: 10.1016/j.pscia.2024.100046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2024-12. Verfasst von Yawen Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with advanced hepatocellular carcinoma (HCC) are not sensitive to sorafenib (SOR), therefore, combination therapy is required. In this study, an improved thin-film dispersion and post-insertion anchoring technique was utilized to construct a dual-targeted co-delivery SOR and docetaxel (DTX) liposome drug delivery system, folate/chondroitin sulfate with SOR/DTX-modified liposomes (FA/CS@SDLP), to jointly enhance the anti-recurrence and metastasis of HCC. FA/CS@SDLP can establish the gradual release of the two drugs because of successful lysosomal escape in the condensed hyaluronidase environment. The results indicated that modification with folate (FA) and chondroitin sulfate (CS) significantly enhanced the cellular uptake of FA/CS@SDLP and the internalization of SOR/DTX in HepG2 cells through FA and CD44 receptor-mediated endocytosis. Compared to free drugs or the mono-targeted liposomal system (FA@SDLP), FA/CS@SDLP presented higher potency against HepG2 cells regarding pro-apoptosis, anti-proliferation, and anti-metastasis (migration and invasion). Moreover, a more satisfactory antitumor efficacy was observed for FA/CS@SDLP in the pulmonary metastasis of HCC in a mouse model. In summary, dual-targeted co-delivery of liposomes can synergistically treat HCC recurrence and metastasis, providing a new approach for the clinically accurate treatment of HCC.

Schlagwörter

Stichwörter der Autor:innen

Advanced hepatocellular carcinomaCombination therapyDocetaxelDual-targeting liposomesSorafenib

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, China.
  • Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao SAR, China.
  • Center of Pharmacokinetics, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China.

Zitieren

APA

Yao, Y., Hu, Y., Meng, X., Feng, F., Xu, F., Wang, G., Yu, H., & Li, J. (2024). Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma. Pharmaceutical Science Advances, 2, 100046. https://doi.org/10.1016/j.pscia.2024.100046

Vancouver

Yao Y, Hu Y, Meng X, Feng F, Xu F, Wang G, et al. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma. Pharmaceutical Science Advances. 2024;2:100046. doi:10.1016/j.pscia.2024.100046

BibTeX
@article{Yao2024,
  author = {Yao, Yawen and Hu, Yue and Meng, Xinwang and Feng, Fenyan and Xu, Feng and Wang, Guangji and Yu, Hua and Li, Juan},
  title = {Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma},
  journal = {Pharmaceutical Science Advances},
  year = {2024},
  volume = {2},
  pages = {100046},
  doi = {10.1016/j.pscia.2024.100046}
}
Kostenlos starten →